top of page



The Course Directors of the 2019 NASH-TAG Conference invites the submission of abstracts regarding advancing therapeutics for and management of non-alcoholic steatohepatitis and fibrosis. Our goal is to provide a comprehensive update on the status of research and to stimulate collaborations, recruitment of subjects, and ideas for the development of other studies. Authors may submit abstracts of completed work, work in progress, or work presented elsewhere within the past 12 months. All abstracts will be peer reviewed and selected for poster or podium presentation.



The deadline for receipt of abstracts is Friday, November 16, 2018. All submitting authors will receive confirmation of their abstract submission via email.


Abstracts will be selected for podium presentation or poster presentation based on scientific merit.  Notification of acceptance for podium and poster presentations will be acknowledged by email on Monday, November 26, 2018.



  • Limit abstracts to one page, typed in 12-point Times New Roman font, single-spaced with one-inch margins, and left justified. 

  • Organize the abstract into Background/Aim, Methods, Results, and Conclusions. Define all abbreviations. Include the abstract category, abstract title, full names and institutional affiliations of all authors, and email address of the corresponding author at the top of the abstract. 

  • Underline the name of the presenting author. Abstracts must not contain copyrighted material unless permission has been obtained by the author. Indicate at the bottom of the page if the abstract has been presented elsewhere and at what meeting. 


Submitted abstracts not meeting the above specifications will be returned.


Any questions regarding abstract submission should be directed to




Deadline of Submission:

Friday, November 16, 2018



Notification of Results:

Monday, November 26, 2018



Clinical Epidemiology – NASH/liver fibrosis 

Diagnostic procedures NASH/liver fibrosis

Therapeutic trials NASH/liver fibrosis – Humans

Clinical trial design

Disease management of NASH/liver fibrosis patients
(including comorbidities)

Pharmacoeconomic/societal aspects

Experimental/basic science, NAFLD/NASH, non-humans

Experimental/basic science, liver fibrosis, non-humans

Pathogenesis, translational science, NAFLD/NASH, liver fibrosis, humans


bottom of page